Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
about
Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discoveryCurrent advances in biomarkers for targeted therapy in triple-negative breast cancerIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesUse of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ERα)-positive mammary adenocarcinomas.Germline variation controls the architecture of somatic alterations in tumorsLack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastasesGenomic instability in breast cancer: pathogenesis and clinical implicationsInterplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.Proteomics and ovarian cancer: integrating proteomics information into clinical carePancreatic adenocarcinomaMolecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer.Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations.A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapyIdentification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.Drug therapy for hereditary cancersCopy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival.Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression.Companion diagnostics: changing patient managementDifferent Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survivalIdentification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.BRCA1 as a tumor suppressor linked to the regulation of epigenetic states: keeping oncomiRs under control.Analysis of terminal duct lobular unit involution in luminal A and basal breast cancers.Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.Ovarian cancer: can proteomics give new insights for therapy and diagnosis?Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers.DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.BRCA1 and BRCA2: different roles in a common pathway of genome protection.Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.Chemoprevention of Rat Mammary Carcinogenesis by Apiaceae SpicesTargeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer.Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference.The 11q13-q14 amplicon: clinicopathological correlations and potential drivers.Predictive biomarkers for cancer therapy with PARP inhibitors.The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair.
P2860
Q26851813-EF58C2FC-A7B7-44D0-A3DC-3C9E1957A65DQ28074202-359714C4-05AF-4FB3-9908-B6A34B2AB065Q29617680-0D604E7B-F43D-4E65-8CCD-6BA9274AB0B5Q33533295-A5356618-E6D9-4E08-ADB5-CF888E252FA9Q33657478-0CEBD663-B6ED-43FC-A3F9-5843AF311EDCQ33707388-305F27BE-413B-4686-B6BF-2F3703608E33Q33988970-36BC03CF-39DE-4830-BFC0-E5D9A9276190Q33998514-857345EE-EEF4-4A84-9246-260DA0F445C6Q34081324-EEB49875-ABF2-4338-A2E7-1F580E1DF024Q34126627-A673DCC0-5A57-48D9-B917-91BDD70BE8D2Q34140498-0E4DEC5A-4982-45C1-B7C1-D1B811340FCBQ34173563-3D13699C-BD2F-4E64-A75C-74545EAAA465Q34308770-11CEF6BE-BC58-4BD7-B517-5DA07C64C471Q34532927-5A45C864-AFE9-4BB2-B35F-1CD6BBF40003Q34599539-AB4CCFDB-AE9A-431D-BD00-4C75360322C0Q35000673-2D3D373B-CD28-461B-A72F-27CD0F5C5E43Q35064727-B2B34E59-B1FC-47BC-AC66-763B01F3B4CDQ35208929-8077B77F-6EF5-4F4E-A77E-A21BE135A8A4Q35281357-2849FBDE-87E9-4BEE-B911-8CA6DA0E0ADCQ35683569-320C32E0-E865-41EB-8246-E221E8F5A001Q35818050-BC0F0B25-9647-49AB-905D-1EC734C8180AQ35958353-A9304D4E-04CB-4CE7-A1C8-0A14909C3174Q36166929-383576E5-BD1E-4972-B0FA-49AF2BE6CADDQ36245467-368201F9-891A-498D-BBBF-C6155F530647Q36245614-B62D8704-097D-48CC-AC54-C6A94D1CED51Q36385670-61C7F360-7F68-4B45-8800-06B65B86A326Q36556331-0E3104C5-44D9-49B4-906F-F1B6E30AE8A1Q36820579-641312BE-E529-4C8C-BCE6-EDA58D73C3C6Q36873792-44BB6A47-2C3D-4A58-8CB6-4E00F215D38CQ36889676-16E3D347-F4AA-4B71-8995-3AF637B3F250Q37149848-3C43EDAD-C235-4693-B700-BA27DA4B3D49Q37678826-E736A03D-93B1-4966-B405-B48E14F90607Q37691006-5CAA3A05-21DB-4C12-9964-9969E1CB5960Q37775105-DCE2B827-726B-4D56-8387-3FA278F407A2Q37933098-73E13685-53EE-4E05-82E6-E644AAD792FEQ37958686-F6B205A0-A4F9-4380-A537-F8802EC9447FQ38059133-A9219A43-7666-4097-8763-800CBB502EE9Q38066149-469C017B-53A7-4C8D-A7E8-668D4F3097D6Q38137764-D6237158-FA83-48C5-92FB-A0FD8A17276AQ38289381-80C3242C-97E0-45F4-B23A-33BEF799102B
P2860
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
@en
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
@nl
type
label
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
@en
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
@nl
prefLabel
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
@en
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
@nl
P2093
P2860
P356
P1476
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
@en
P2093
Jon Gunnlaugur Jonasson
Jorunn Erla Eyfjord
Kristrun Olafsdottir
Margret Steinarsdottir
Olafur Andri Stefansson
Oskar Thor Johannsson
Sigridur Valgeirsdottir
P2860
P2888
P356
10.1186/BCR2334
P577
2009-07-09T00:00:00Z
P5875
P6179
1006585003